Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells ...

The following is a summary of “Identification of a pancreatic stellate cell gene signature and lncRNA interactions associated ...

Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...

It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...

Among those who have had gestational diabetes, about 35% will develop type 2 diabetes within a decade. A new study led by Dr.

Diabetes is a leading cause of global mortality and disability, and its economic burden is substantial. This Review focuses on type 2 diabetes, which makes up 90–95% of all diabetes cases. Type 2 ...

Recent advances in immunotherapy have revealed a promising frontier in Type 1 diabetes treatment: outsmarting rather than ...

Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updat ...

Researchers from Tokyo Metropolitan University have uncovered a significant link between age-related diabetes and the loss of ...

Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results ...

HANGZHOU, China I January 10, 2025 I Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative ...